Identification of Genes of Interest for Severe Forms of Preeclampsia
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-45
SponsorUniversity Hospital, Strasbourg, France
About this trial
Preeclampsia is a pregnancy complication characterized by high blood pressure associated with damage to various organs, especially the kidneys. It happens in about 1 to 5% of pregnant women and can cause serious problems for both the mother and the baby.
Several multi-omics studies have already been conducted on preeclampsia, with promising results. However, this is preliminary data that requires further studies. The molecular markers identified in this type of study could potentially be used, first of all, for the early screening of this condition, which is not yet reliably achievable. In addition, the knowledge gained from this research would help us better understand the pathophysiology of preeclampsia. Therefore, the investigators' goal is to carry out a multi-omics analysis of preeclampsia to uncover the genetic and molecular mechanisms involved in this condition.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Severe hypertension (SBP ≥ 160 mmHg and/or DBP ≥ 110 mmHg) or uncontrolled.
Proteinuria > 3g/24h.
Creatinine ≥ 90 μmol/L.
Oliguria ≤ 500 mL/24h or ≤ 25 mL/h.
Disqualifiers
Diabetes prior to pregnancy
Multiple pregnancy
Long-term medication treatment (except usual pregnancy supplements)
Smoking, alcohol, or drug use during pregnancy
Trial population
100 pregnant women recruited at a single center. Participants will be divided into two groups: 50 pregnant women diagnosed with severe preeclampsia and 50 healthy pregnant women without any pregnancy-related pathology serving as the control group. Biological samples and clinical data will be collected at enrollment to identify genetic and molecular markers associated with severe preeclampsia.
Trial design
Design model
Other
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
100 Participants
are grouped into 2 trial groupsGroup A: Experimental group P
Group B: Control group T
Trial outcomes
Primary outcomes
1
Identifying genetic and molecular markers associated with severe forms of preeclampsia
Identify, from blood, urine, and placental samples, the changes in genetic and molecular signatures as well as in cell composition associated with severe forms of preeclampsia, by comparing the expression levels of the signatures and the relative abundance of different cell populations between patients with severe preeclampsia and control patients.
Time frame
At enrollmentLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: